Ariel E Marciscano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1839100/publications.pdf

Version: 2024-02-01

55 papers 2,274 citations

567281 15 h-index 36 g-index

56 all docs 56 docs citations

56 times ranked 4340 citing authors

#	Article	IF	CITATIONS
1	<scp>LAG</scp> 3 (<scp>CD</scp> 223) as a cancer immunotherapy target. Immunological Reviews, 2017, 276, 80-96.	6.0	664
2	Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2018, 100, 916-925.	0.8	257
3	Resistance of Glioblastoma-Initiating Cells to Radiation Mediated by the Tumor Microenvironment Can Be Abolished by Inhibiting Transforming Growth Factor- \hat{l}^2 . Cancer Research, 2012, 72, 4119-4129.	0.9	214
4	Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy. Clinical Cancer Research, 2018, 24, 5058-5071.	7.0	213
5	Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment. Cancer Immunology Research, 2017, 5, 992-1004.	3.4	149
6	White paper on microbial anti-cancer therapy and prevention., 2018, 6, 78.		108
7	Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade. Neuro-Oncology, 2016, 18, 863-872.	1.2	91
8	The role of dendritic cells in cancer and anti-tumor immunity. Seminars in Immunology, 2021, 52, 101481.	5.6	91
9	Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes. Journal of Neurosurgery, 2016, 124, 106-114.	1.6	86
10	TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors. Cancer Immunology Research, 2018, 6, 422-433.	3.4	59
11	Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities. International Journal of Radiation Oncology Biology Physics, 2021, 110, 35-52.	0.8	54
12	Radiation Therapy and the In Situ Vaccination Approach. International Journal of Radiation Oncology Biology Physics, 2020, 108, 891-898.	0.8	46
13	Stereotactic body radiation therapy in pancreatic cancer: the new frontier. Expert Review of Anticancer Therapy, 2014, 14, 1461-1475.	2.4	31
14	Role of noninvasive molecular imaging in determining response. Advances in Radiation Oncology, 2018, 3, 534-547.	1.2	25
15	Long-term Treatment Response and Patient Outcomes for Vestibular Schwannoma Patients Treated with Hypofractionated Stereotactic Radiotherapy. Frontiers in Oncology, 2017, 7, 200.	2.8	21
16	3D quantitative assessment of response to fractionated stereotactic radiotherapy and single-session stereotactic radiosurgery of vestibular schwannoma. European Radiology, 2016, 26, 849-857.	4.5	15
17	Management of High-Risk Localized Prostate Cancer. Advances in Urology, 2012, 2012, 1-11.	1.3	13
18	Is there a role for an external beam boost in cervical cancer radiotherapy?â€. Frontiers in Oncology, 2013, 3, 3.	2.8	13

#	Article	IF	Citations
19	Introduction to the Medical Professions Through an Innovative Medical Student-Run Pipeline Program. Journal of the National Medical Association, 2011, 103, 832-838.	0.8	12
20	Development of a novel multiplexed assay for quantification of transforming growth factor- \hat{l}^2 (TGF- \hat{l}^2). Growth Factors, 2015, 33, 79-91.	1.7	11
21	Long-term Outcomes With Planned Multistage Reduced Dose Repeat Stereotactic Radiosurgery for Treatment of Inoperable High-Grade Arteriovenous Malformations: An Observational Retrospective Cohort Study. Neurosurgery, 2017, 81, 136-146.	1.1	9
22	Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 309.e7-309.e14.	1.6	8
23	Does Prophylactic Nodal Irradiation Inhibit Potential Synergy Between Radiation Therapy and Immunotherapy?. International Journal of Radiation Oncology Biology Physics, 2016, 96, S88.	0.8	7
24	Evaluating Post-Radiotherapy Laryngeal Function with Laryngeal Videostroboscopy in Early Stage Glottic Cancer. Frontiers in Oncology, 2017, 7, 124.	2.8	7
25	Clinical Outcomes of Combined Prostate- and Metastasis-Directed Radiation Therapy for the Treatment of De Novo Oligometastatic Prostate Cancer. Advances in Radiation Oncology, 2020, 5, 1213-1224.	1.2	7
26	Concurrent Immunotherapy and Stereotactic Radiosurgery for Brain Metastases Is Associated With a Decreased Incidence of New Intracranial Metastases. International Journal of Radiation Oncology Biology Physics, 2015, 93, E102.	0.8	6
27	Avelumab: is it time to get excited?. Expert Review of Anticancer Therapy, 2018, 18, 815-821.	2.4	6
28	Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies. Current Treatment Options in Oncology, 2018, 19, 16.	3.0	5
29	Antiangiogenic Therapies and Extracranial Metastasis in Glioblastoma: A Case Report and Review of the Literature. Case Reports in Oncological Medicine, 2015, 2015, 1-5.	0.3	4
30	Atypical Histopathological Features and the Risk of Treatment Failure in Nonmalignant Meningiomas: A Multi-Institutional Analysis. World Neurosurgery, 2020, 133, e804-e812.	1.3	4
31	Parallels Between the Antiviral State and the Irradiated State. Journal of the National Cancer Institute, 2021, 113, 969-979.	6.3	4
32	Avelumab demonstrates promise in advanced NSCLC. Oncotarget, 2017, 8, 102767-102768.	1.8	3
33	Torus Palatinus. Baylor University Medical Center Proceedings, 2014, 27, 259-259.	0.5	2
34	The Winds of Change: Emerging Therapeutics in Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 382-390.	3.8	2
35	CDK12 Gene Alterations in Prostate Cancer: Present, but Clinically Actionable?. European Urology, 2020, 78, 680-681.	1.9	2
36	Rituximab Fails to Reduce Histologic Transformation (HT) Rate of Follicular Lymphoma (FL) to Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2008, 112, 837-837.	1.4	2

#	Article	IF	CITATIONS
37	Non-Invasive Molecular Imaging to Elucidate Mechanisms of Synergy of Immune Checkpoint Blockade and Stereotactic Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, S202.	0.8	1
38	Development of a Novel Multiplexed-TGF \hat{l}^2 Assay. International Journal of Radiation Oncology Biology Physics, 2011, 81, S755.	0.8	0
39	TGFÎ ² Inhibition Radiosensitizes Murine Glioblastoma Cells and Decreases Neurosphere-forming Capacity. International Journal of Radiation Oncology Biology Physics, 2011, 81, S714.	0.8	0
40	Brachytherapy versus External Beam Boost in Cervical Cancer Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, S468.	0.8	0
41	Benign Meningiomas With Atypical Features: Correlation of Histopathological Features With Clinical Outcomes. International Journal of Radiation Oncology Biology Physics, 2013, 87, S159.	0.8	0
42	Long-Term Follow-Up of Adaptive Multistage Stereotactic Radiosurgery for Treatment of High-Grade Arteriovenous Malformations. International Journal of Radiation Oncology Biology Physics, 2014, 90, S297.	0.8	0
43	Video Laryngostroboscopy Demonstrates Post–Radiation Therapy Improvement in Dysphonia in Early-Stage Glottic Larynx Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, S99.	0.8	0
44	Correlation of Imaging Characteristics With Histopathological WHO Grade in Meningiomas. International Journal of Radiation Oncology Biology Physics, 2015, 93, E86.	0.8	0
45	Long-term Treatment Response and Patient Outcomes for Vestibular Schwannoma Patients Treated With Hypofractionated Stereotactic Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 93, S169-S170.	0.8	0
46	Evaluating Radiological Changes in Vestibular Schwannoma Patients Treated With Hypofractionated Stereotactic Radiation Therapy: A Potential Role for a Novel 3-D Quantitative Volumetric Assessment Tool. International Journal of Radiation Oncology Biology Physics, 2015, 93, E114-E115.	0.8	0
47	Immediate Versus Delayed Treatment Does Not Influence Long-term Outcomes After Radiation Therapy for Vestibular Schwannoma. International Journal of Radiation Oncology Biology Physics, 2015, 93, E118.	0.8	0
48	Significant Differences in Planning Target Volumes Based on Immediate Postoperative Imaging Versus Radiation Therapy Planning Imaging: Implications for Treatment Planning for Malignant Glioma. International Journal of Radiation Oncology Biology Physics, 2016, 96, E120.	0.8	0
49	Survival Outcomes Following Combination Radiotherapy and Immune Checkpoint Inhibitors. International Journal of Radiation Oncology Biology Physics, 2017, 99, E583.	0.8	0
50	Atypical Histopathological Features and the Risk of Progression/Recurrence in WHO Grade I-II Meningiomas. International Journal of Radiation Oncology Biology Physics, 2018, 102, e226.	0.8	0
51	Abstract LB-361: Radiosensitization and decreased neurosphere-forming capacity with TGF \hat{l}^2 inhibition in glioma cells. , 2011, , .		0
52	Abstract A87: Preliminary results of a phase II study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer , 2011 , , .		0
53	Principles of image-guided hypofractionated radiotherapy of spine metastases. , 2016, , 147-160.		0
54	Abstract PRO3: Prophylactic nodal irradiation abrogates the synergy of tumor radiotherapy and immune checkpoint blockade. , 2017, , .		0